Cytek Biosciences, Inc.
CTKB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.89 | 0.18 | -12.75 | 13.59 |
| FCF Yield | 2.58% | 0.04% | -1.61% | 0.01% |
| EV / EBITDA | -76.34 | -245.15 | 114.82 | 174.84 |
| Quality | ||||
| ROIC | -4.92% | -4.88% | -0.75% | 1.12% |
| Gross Margin | 55.43% | 56.69% | 61.56% | 61.86% |
| Cash Conversion Ratio | -4.22 | -0.43 | -4.92 | 1.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.91% | 14.69% | 20.89% | 30.27% |
| Free Cash Flow Growth | 4,713.66% | 102.05% | -8,407.89% | -98.05% |
| Safety | ||||
| Net Debt / EBITDA | 8.14 | 34.75 | -29.21 | -35.06 |
| Interest Coverage | 0.00 | -13.45 | -0.71 | 3.70 |
| Efficiency | ||||
| Inventory Turnover | 2.04 | 1.37 | 1.31 | 1.52 |
| Cash Conversion Cycle | 267.05 | 358.71 | 359.63 | 302.80 |